NCT07416409 2026-02-18Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast CancerDeraya UniversityCompleted80 enrolled
NCT00680901 2025-08-07LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus LapatinibNovartisPhase 3 Completed545 enrolled 24 charts